Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.

Pfizer ponders Viagra lessons to chart first obesity drug launch

Pfizer Inc. is drawing on lessons learned years ago from rolling out Viagra as it maps out the launch of its first obesity ...

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

Pfizer made one thing clear this week: It's officially back in the obesity race.
Medical Dialogues

Once-Monthly GLP-1 Injection Shows Significant Weight Loss Without Plateau in non diabetics in Phase 2 trial

Pfizer reported that its ultra-long-acting, once-monthly GLP-1 injectable achieved up to 12.3% placebo-adjusted weight loss ...
MM&M

Pfizer’s birth control injection has a new safety label, reflecting potential brain tumors

Pfizer’s battle over the safety label for its birth control injection has finally come to a close. The pharma giant announced that the Food and Drug Administration approved its new safety warning ...